Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials

Abstract Introduction Deucravacitinib, a novel, oral, selective allosteric tyrosine kinase 2 inhibitor, demonstrated superiority versus placebo and apremilast in the POETYK PSO-1 and PSO-2 studies. We describe patient-reported outcomes with deucravacitinib treatment versus placebo and apremilast in...

Full description

Bibliographic Details

Published in:	Dermatology and Therapy
Main Authors:	April W. Armstrong, Matthias Augustin, Jennifer L. Beaumont, Tan P. Pham, Stacie Hudgens, Kenneth B. Gordon, Joe Zhuo, Brandon Becker, Yichen Zhong, Renata M. Kisa, Subhashis Banerjee, Kim A. Papp
Format:	Article
Language:	English
Published:	Adis, Springer Healthcare 2024-07-01
Subjects:	Clinical trial Minimum clinically important difference Psoriasis Quality of life Treatment efficacy
Online Access:	https://doi.org/10.1007/s13555-024-01224-x